CHEK - Check-Cap Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.5500
+0.0900 (+3.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.4600
Open2.4500
Bid2.5100 x 900
Ask2.6000 x 1300
Day's Range2.4349 - 2.5900
52 Week Range1.6200 - 19.7800
Volume52,629
Avg. Volume395,990
Market Cap21.001M
Beta (3Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-2.6090
Earnings DateMar 7, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Trade prices are not sourced from all markets
  • Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening
    PR Newswire12 days ago

    Check-Cap Initiates U.S. Pilot Study of C-Scan® for Colorectal Cancer Screening

    ISFIYA, Israel, April 8, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the initiation of its U.S. pilot study of the C-Scan® system, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested the C-Scan® capsule at the New York University School of Medicine. "The pilot study initiation is a critical milestone on our path for developing and potentially commercializing the C-Scan® system in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.

  • Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results
    PR Newswire22 days ago

    Check-Cap Reports Fourth Quarter and Full-Year 2018 Financial Results

    ISFIYA, Israel , March 28, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer
    PR Newswirelast month

    Check-Cap Announces Appointment of Mira Rosenzweig as Chief Financial Officer

    ISFIYA, Israel , March 18, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (Nasdaq: CHEK) (Nasdaq: CHEKW), (Nasdaq: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®
    PR Newswire2 months ago

    Check-Cap Announces Institutional Review Board Approval to Initiate U.S. Pilot Study of C-Scan®

    ISFIYA, Israel, Feb. 12, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW), (CHEKZ), a clinical-stage medical diagnostics company advancing the development of C-Scan®, the first and only preparation-free capsule based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced it has received Institutional Review Board (IRB) approval from New York University School of Medicine to initiate a U.S. pilot study of the C-Scan® system. "We are excited to receive IRB approval as this important milestone enables Check-Cap to bring the C-Scan® system into the clinic in the U.S.," said Alex Ovadia, chief executive officer of Check-Cap.

  • Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering
    PR Newswire2 months ago

    Check-Cap Ltd. Announces Closing of $7.5 Million Registered Direct Offering

    ISFIYA, Israel, Feb. 7, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced the closing of its previously announced registered direct offering with certain institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit. Each unit consisted of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.

  • Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering
    PR Newswire2 months ago

    Check-Cap Ltd. Announces $7.5 Million Registered Direct Offering

    ISFIYA, Israel, Feb. 4, 2019 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (CHEKZ), a clinical-stage medical diagnostics company offering C-Scan®, the first and only preparation free capsule-based screening method for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit, in a registered direct offering. Each unit consists of (i) one ordinary share (or ordinary share equivalent), and (ii) a warrant to purchase one half ordinary share.

  • PR Newswire4 months ago

    Check-Cap Announces FDA Conditional Approval of IDE to Initiate U.S. Pilot Study of C-Scan®

    Study to begin upon review and approval of Institutional Review Board (IRB) ISFIYA, Israel , Dec. 13, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) ...

  • GlobeNewswire5 months ago

    Analysis: Positioning to Benefit within Autoliv, Science Applications International, Trecora Resources, Ardmore Shipping, Check-Cap, and Sharps Compliance — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Check-Cap Reports Third Quarter 2018 Financial Results
    PR Newswire5 months ago

    Check-Cap Reports Third Quarter 2018 Financial Results

    Announced Interim Results from Post-CE Approval Study of C-Scan® Announces Update on Scheduled Initiation of U.S. Pilot Study ISFIYA, Israel , Nov. 5, 2018 /PRNewswire/ --  Check-Cap Ltd. (the "Company" ...

  • PR Newswire6 months ago

    Check-Cap Announces IDE Submission to FDA for Its C-Scan® System

    If Approved, U.S. Pilot Study Anticipated to Commence in 4Q 2018 ISFIYA, Israel , Oct. 9, 2018 /PRNewswire/ --  Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: ...

  • Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System
    PR Newswire7 months ago

    Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System

    ISFIYA, Israel, Sept. 5, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer (CRC) screening, today announced it has received approval from the Israeli Ministry of Health, the Medical Device Division (known as "AMAR"), to initiate commercial sales in Israel of the C-Scan system that received CE Mark approval in January 2018. Alex Ovadia, Chief Executive Officer of Check-Cap, commented, "We are excited to receive approval from the Israeli Ministry of Health to initiate commercial sales in Israel of our C-Scan system.

  • PR Newswire7 months ago

    Check-Cap Announces Promising Interim Results from its Ongoing Post-CE Approval Study of C-Scan® System Version 3

    ISFIYA, Israel, Sept. 4, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule-based device for preparation-free, colorectal cancer (CRC) screening, today announced the interim results for its post-CE approval study of the C-Scan system Version 3. Data from the multi-center clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon. The objective of the study is to assess safety and clinical performance of the C-Scan system Version 3 in detecting patients with polyps.

  • Check-Cap Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference
    PR Newswire8 months ago

    Check-Cap Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference

    ISFIYA, Israel, Aug. 29, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule-based device for preparation-free colorectal cancer screening, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.rodmanevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

  • Check-Cap Reports Second Quarter 2018 Financial Results
    PR Newswire9 months ago

    Check-Cap Reports Second Quarter 2018 Financial Results

    ISFIYA, Israel , July 31, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • ACCESSWIRE9 months ago

    Free Research Reports on DexCom and Three More Medical Research Stocks

    Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...

  • ACCESSWIRE11 months ago

    Check-Cap to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKZ, CHEKW), a clinical-stage medical diagnostics company engaged in the ...

  • ACCESSWIRE11 months ago

    Complimentary Technical Snapshots on Bruker and Three More Medical Research Stocks

    Research reports have been issued by WallStEquities.com on BioTelemetry Inc. (NASDAQ: BEAT), Bruker Corp. (NASDAQ: BRKR), Cancer Genetics Inc. (NASDAQ: CGIX), and Check-Cap Ltd (NASDAQ: CHEK). Companies in the Medical Laboratories and Research category is very small from a dividend perspective.

  • Check-Cap Announces Publication of CE Mark Multicenter Clinical Study Results on C-Scan® in Gut
    PR Newswire11 months ago

    Check-Cap Announces Publication of CE Mark Multicenter Clinical Study Results on C-Scan® in Gut

    ISFIYA, Israel, May 22, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (CHEKW) (CHEKZ), a clinical stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule preparation-free, colorectal cancer screening, today announced that the results of its multicenter clinical study that examined C-Scan safety and efficacy (compared to FIT and colonoscopy) for polyp detection confirmed by ensuing colonoscopy, which was submitted for capsule CE Mark, received in January 2018, has been published in Gut, an official peer-reviewed journal of the British Society of Gastroenterology. The article, entitled "A Novel Prep-Less X-Ray Imaging Capsule for Colon Cancer Screening: A Feasibility Study," reported that in 45 analyzed patients, capsule and FIT sensitivity (ability to correctly identify polyps) were 44% and 37%, respectively, with capsule sensitivity increasing to 78% when 50% of the colon surface area was imaged and a linear correlation was observed between imaged area and sensitivity.

  • Check-Cap Reports First Quarter 2018 Financial Results
    PR Newswire11 months ago

    Check-Cap Reports First Quarter 2018 Financial Results

    ISFIYA, Israel , May 17, 2018 /PRNewswire/ --Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company ...

  • Check-Cap Announces Closing of $20.2 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Securities
    PR Newswire11 months ago

    Check-Cap Announces Closing of $20.2 Million Public Offering and Full Exercise of the Underwriter's Option to Purchase Additional Securities

    ISFIYA, Israel, May 8, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK; CHEKW; CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today announced the closing of its previously announced underwritten public offering of 3,189,381 units, with each unit consisting of one ordinary share (or ordinary share equivalent) and one Series C warrant to purchase one ordinary share, along with the exercise in full by the underwriter of its option to purchase an additional 478,407 ordinary shares and Series C warrants to purchase up to 478,407 ordinary shares.

  • Is Check-Cap Ltd (NASDAQ:CHEK) Undervalued?
    Simply Wall St.last year

    Is Check-Cap Ltd (NASDAQ:CHEK) Undervalued?

    Check-Cap Ltd (NASDAQ:CHEK), a medical equipment company based in Israel, saw a significant share price rise of over 20% in the past couple of months on the NasdaqCM. As aRead More...

  • ACCESSWIRElast year

    Today’s Research Reports on Stocks to Watch: Check-Cap and EyePoint Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 25, 2018 / Shares of Check-Cap and EyePoint Pharmaceuticals both experienced some unusual activity in Tuesday trading with both stocks seeing significant gains on high ...